Get the Stockscreener App
61.40
0.20%
0.12
Guardant Health Inc stock is traded at $61.40, with a volume of 1.98M.
It is up +0.20% in the last 24 hours and up +32.76% over the past month.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
See More
Previous Close:
$61.28
Open:
$61.34
24h Volume:
1.98M
Relative Volume:
0.85
Market Cap:
$7.66B
Revenue:
$692.26M
Net Income/Loss:
$-512.41M
P/E Ratio:
-14.48
EPS:
-4.24
Net Cash Flow:
$-274.36M
1W Performance:
+4.28%
1M Performance:
+32.76%
6M Performance:
+43.22%
1Y Performance:
+120.31%
1-Day Range:
$60.84
$62.81
1-Week Range:
$57.41
$62.81
52-Week Range:
$20.14
$62.81
Guardant Health Inc Stock (GH) Company Profile
Name
Guardant Health Inc
Sector
Industry
Phone
855-698-8887
Address
3100 HANOVER STREET, PALO ALTO
Compare GH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
61.40 | 7.42B | 692.26M | -512.41M | -274.36M | -4.24 |
|
TMO
Thermo Fisher Scientific Inc
|
499.99 | 184.10B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
211.80 | 149.66B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
645.55 | 51.03B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
121.63 | 33.56B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
191.15 | 32.73B | 15.70B | 1.24B | 2.01B | 6.91 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Jun-28-24 | Upgrade | Guggenheim | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-24-24 | Resumed | Craig Hallum | Buy |
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Sep-27-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-26-23 | Upgrade | Citigroup | Neutral → Buy |
| May-05-23 | Initiated | UBS | Buy |
| Mar-09-23 | Downgrade | Citigroup | Buy → Neutral |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Nov-01-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-19-22 | Initiated | Craig Hallum | Buy |
| Oct-06-22 | Initiated | Stephens | Overweight |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jun-03-22 | Initiated | Piper Sandler | Overweight |
| Apr-28-22 | Resumed | BTIG Research | Buy |
| Feb-24-22 | Reiterated | Canaccord Genuity | Buy |
| Feb-24-22 | Reiterated | Citigroup | Buy |
| Feb-24-22 | Reiterated | Cowen | Outperform |
| Feb-24-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-24-22 | Reiterated | SVB Leerink | Outperform |
| Feb-24-22 | Reiterated | Stifel | Buy |
| Feb-24-22 | Reiterated | Wells Fargo | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| Jun-03-21 | Initiated | Goldman | Buy |
| May-25-21 | Initiated | Wells Fargo | Overweight |
| Jan-11-21 | Initiated | Stifel | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Jun-12-20 | Initiated | BTIG Research | Buy |
| Feb-21-20 | Initiated | Guggenheim | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Aug-07-19 | Reiterated | Canaccord Genuity | Buy |
| Apr-16-19 | Initiated | Canaccord Genuity | Buy |
| Apr-10-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-28-19 | Reiterated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | JP Morgan | Overweight |
| Oct-29-18 | Initiated | William Blair | Outperform |
View All
Guardant Health Inc Stock (GH) Latest News
Guardant Health Director Tariq Musa Sells 116 Shares at $59.02 on 2025-08-19 - AInvest
Exas, Guardant, Gilead among gainers as Supreme Court ensures free preventive care - MSN
Guardant Health raises 2025 revenue outlook to $915M–$925M amid strong Shield adoption and oncology momentum - MSN
Is Guardant Health Inc. impacted by rising ratesCEO Change & Real-Time Stock Movement Alerts - thegnnews.com
Detecting price anomalies in Guardant Health Inc. with AI2025 Breakouts & Breakdowns & Intraday High Probability Alerts - Newser
Can machine learning forecast Guardant Health Inc. recovery2025 Biggest Moves & AI Powered Market Entry Strategies - Newser
Live market analysis of Guardant Health Inc.2025 Key Lessons & Low Risk High Win Rate Picks - Newser
Can Guardant Health Inc. hit a new high this monthSwing Trade & Fast Momentum Stock Entry Tips - Newser
Guardant Health Awards Stock Options and RSUs to New Employees Under Nasdaq Listing Rule 5635(c)(4) - AInvest
Guardant Health Inc. Stock Approaches Key Moving Average2025 Bull vs Bear & Long Hold Capital Preservation Tips - metal.it
Will Guardant Health Inc. rebound enough to break evenJuly 2025 Decliners & Precise Entry and Exit Recommendations - Newser
Can Guardant Health Inc. be recession proof2025 Stock Rankings & Verified Short-Term Trading Plans - thegnnews.com
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - 01net
What’s the analyst consensus on Guardant Health Inc.July 2025 Review & Weekly Setup with ROI Potential - kangso.co.kr
Guardant Health Inc. (GH) Crosses Above Average Analyst Target Price of $59.43. - AInvest
Market Participants Recognise Guardant Health, Inc.'s (NASDAQ:GH) Revenues Pushing Shares 26% Higher - 富途牛牛
Guardant Health Inc. Building a Base Near SupportQuarterly Trade Review & AI Powered Buy and Sell Recommendations - classian.co.kr
Guardant Health Hits 52-Week High on $210M Volume Ranking 463rd Amid Institutional BuySell Splits - AInvest
Guardant Health stock reaches 52-week high at 59.25 USD By Investing.com - Investing.com Nigeria
Guardant Health stock reaches 52-week high at 59.25 USD - Investing.com
Cathie Wood’s ARK buys Bullish stock, sells Shopify and Guardant Health - Investing.com India
Astrana Health, agilon health, Guardant Health, AdaptHealth, and Pediatrix Medical Group Stocks Trade Up, What You Need To Know - TradingView
Astrana Health, agilon health, Guardant Health, AdaptHealth, and Pediatrix Medical Group Stocks Trade Up, What You Need To Know | FinancialContent - FinancialContent
Guardant Health at Canaccord Conference: Strategic Growth Unveiled By Investing.com - Investing.com Canada
GH Q2 Deep Dive: Strong Volume Growth and Product Expansion Amid Profitability Challenges - Yahoo Finance
The 5 Most Interesting Analyst Questions From Guardant Health’s Q2 Earnings Call - Yahoo Finance
Multi Cancer Early Detection Market Forecast Report 2025-2033: A $4.3 Billion Market by 2033, as Market Set to Quadruple from $1 Billion Valuation in 2024 - uk.finance.yahoo.com
Exact Sciences Teams Up With Freenome to Take on Guardant Health in Colorectal Cancer Screening - MedCity News
Weekly Market Update: Stocks Rise as Basic Materials and Tech Gain - Morningstar
Guardant Health Surges 7.62% on $250M Volume Despite 396th Market Activity Rank - AInvest
Guardant Health Surges 13% on 197% Volume Spike Ranks 269th in Market Activity - AInvest
Guardant Health stock hits 52-week high at 53.49 USD By Investing.com - Investing.com South Africa
Guardant Health stock hits 52-week high at 53.49 USD - Investing.com
Guardant Health Soars 17.2% on Q2 Earnings Beat - AInvest
Exact Sciences acquires rights to rival Freenome’s blood-based colon cancer test - statnews.com
Multi-Cancer Early Detection Market Set to Revolutionize Cancer Diagnosis by 2034 | Driven by Liquid Biopsy Innovations and AI Integration - PharmiWeb.com
The Oncology Institute, Inc. shares rise 3.94% intraday after American Cancer Society and Guardant Health partnership. - AInvest
American Cancer Society and Guardant Health Partner to Expand Cancer Screening Access and Advance Health Equity - Business Wire
Is It Too Late to Sell Guardant Health Inc.Intraday Trend Analysis for Fast Gains Released - beatles.ru
Why is Guardant Health Inc. stock attracting strong analyst attentionRobust financial gains - Jammu Links News
What drives Guardant Health Inc. stock priceUnlock daily market insights for better trades - Jammu Links News
What is the risk reward ratio of investing in Guardant Health Inc. stockExceptional market positioning - Jammu Links News
Should I hold or sell Guardant Health Inc. stock in 2025Maximize portfolio value with expert tips - Jammu Links News
What catalysts could drive Guardant Health Inc. stock higher in 2025Exceptional trading results - Jammu Links News
How volatile is Guardant Health Inc. stock compared to the marketHarness the power of proven investment plans - Jammu Links News
What institutional investors are buying Guardant Health Inc. stockSignificant capital appreciation - Jammu Links News
Does Guardant Health Inc. stock perform well during market downturnsUnlock powerful portfolio management tools - Jammu Links News
What is Guardant Health Inc. company’s growth strategyMarket-leading growth rates - Jammu Links News
Is Guardant Health Inc. a growth stock or a value stockRapid growth trajectories - Jammu Links News
What are Guardant Health Inc. company’s key revenue driversStrong return on assets - Jammu Links News
Is Guardant Health Inc. stock overvalued or undervaluedAchieve breakthrough performance with smart picks - Jammu Links News
Guardant Health Inc Stock (GH) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.05%
1.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):